Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 838.73 Thousand USD | -2.02% |
| 2022 | 856.02 Thousand USD | 27.3% |
| 2021 | 672.46 Thousand USD | 0.54% |
| 2020 | 668.87 Thousand USD | 0.36% |
| 2019 | 666.5 Thousand USD | -36.97% |
| 2018 | 1.05 Million USD | 12.36% |
| 2017 | 941.16 Thousand USD | -41.0% |
| 2016 | 1.59 Million USD | -96.34% |
| 2015 | 43.63 Million USD | 8.38% |
| 2014 | 40.25 Million USD | 101.89% |
| 2013 | 19.94 Million USD | 215.14% |
| 2012 | 6.32 Million USD | -6.91% |
| 2011 | 6.79 Million USD | -24.31% |
| 2010 | 8.97 Million USD | 759.15% |
| 2009 | 1.04 Million USD | -36.78% |
| 2008 | 1.65 Million USD | 18.56% |
| 2007 | 1.39 Million USD | -18.11% |
| 2006 | 1.7 Million USD | 14.15% |
| 2005 | 1.49 Million USD | -9.75% |
| 2004 | 1.65 Million USD | 28.84% |
| 2003 | 1.28 Million USD | -14.11% |
| 2002 | 1.49 Million USD | -86.12% |
| 2001 | 10.75 Million USD | 275.39% |
| 2000 | 2.86 Million USD | 34.88% |
| 1999 | 2.12 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 821.95 Thousand USD | -9.61% |
| 2024 Q1 | 909.38 Thousand USD | 8.42% |
| 2023 Q3 | 873.18 Thousand USD | -4.51% |
| 2023 Q1 | 882.79 Thousand USD | 3.13% |
| 2023 Q2 | 914.44 Thousand USD | 3.59% |
| 2023 FY | 838.73 Thousand USD | -2.02% |
| 2023 Q4 | 838.73 Thousand USD | -3.95% |
| 2022 Q2 | 761.14 Thousand USD | 43.35% |
| 2022 FY | 856.02 Thousand USD | 27.3% |
| 2022 Q4 | 856.02 Thousand USD | 19.87% |
| 2022 Q3 | 714.15 Thousand USD | -6.17% |
| 2022 Q1 | 530.97 Thousand USD | -21.04% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q3 | 672.46 Thousand USD | 0.0% |
| 2021 Q4 | 672.46 Thousand USD | 0.0% |
| 2021 FY | 672.46 Thousand USD | 0.54% |
| 2020 Q4 | 668.87 Thousand USD | 0.0% |
| 2020 FY | 668.87 Thousand USD | 0.36% |
| 2019 Q4 | 666.5 Thousand USD | -49.63% |
| 2019 FY | 666.5 Thousand USD | -36.97% |
| 2019 Q1 | 1.17 Million USD | 10.95% |
| 2019 Q2 | 1.34 Million USD | 14.76% |
| 2019 Q3 | 1.32 Million USD | -1.72% |
| 2018 Q1 | 1.15 Million USD | 22.95% |
| 2018 Q4 | 1.05 Million USD | -21.18% |
| 2018 Q2 | 1.09 Million USD | -5.24% |
| 2018 Q3 | 1.34 Million USD | 22.36% |
| 2018 FY | 1.05 Million USD | 12.36% |
| 2017 Q3 | 1.74 Million USD | -9.63% |
| 2017 FY | 941.16 Thousand USD | -41.0% |
| 2017 Q1 | 1.61 Million USD | 1.06% |
| 2017 Q2 | 1.93 Million USD | 19.75% |
| 2017 Q4 | 941.16 Thousand USD | -46.05% |
| 2016 FY | 1.59 Million USD | -96.34% |
| 2016 Q2 | 2.78 Million USD | -94.22% |
| 2016 Q4 | 1.59 Million USD | -13.95% |
| 2016 Q3 | 1.85 Million USD | -33.53% |
| 2016 Q1 | 48.29 Million USD | 10.68% |
| 2015 Q2 | 27.23 Million USD | -15.75% |
| 2015 FY | 43.63 Million USD | 8.38% |
| 2015 Q1 | 32.33 Million USD | -19.69% |
| 2015 Q4 | 43.63 Million USD | 220.37% |
| 2015 Q3 | 13.61 Million USD | -50.0% |
| 2014 Q2 | 49.71 Million USD | 97.23% |
| 2014 Q3 | 47.98 Million USD | -3.48% |
| 2014 Q4 | 40.25 Million USD | -16.11% |
| 2014 FY | 40.25 Million USD | 101.89% |
| 2014 Q1 | 25.2 Million USD | 26.42% |
| 2013 Q3 | 16.46 Million USD | 44.06% |
| 2013 Q2 | 11.43 Million USD | 4.13% |
| 2013 FY | 19.94 Million USD | 215.14% |
| 2013 Q4 | 19.94 Million USD | 21.08% |
| 2013 Q1 | 10.97 Million USD | 73.49% |
| 2012 FY | 6.32 Million USD | -6.91% |
| 2012 Q2 | 7.52 Million USD | -80.73% |
| 2012 Q4 | 6.32 Million USD | -13.88% |
| 2012 Q1 | 39.03 Million USD | 474.32% |
| 2012 Q3 | 7.34 Million USD | -2.34% |
| 2011 Q2 | 5.45 Million USD | -24.88% |
| 2011 Q4 | 6.79 Million USD | -19.96% |
| 2011 FY | 6.79 Million USD | -24.31% |
| 2011 Q1 | 7.26 Million USD | -19.15% |
| 2011 Q3 | 8.49 Million USD | 55.71% |
| 2010 FY | 8.97 Million USD | 759.15% |
| 2010 Q1 | 1.02 Million USD | -1.51% |
| 2010 Q2 | 5.93 Million USD | 476.45% |
| 2010 Q3 | 7.78 Million USD | 31.14% |
| 2010 Q4 | 8.97 Million USD | 15.4% |
| 2009 Q4 | 1.04 Million USD | -3.33% |
| 2009 Q1 | 1.47 Million USD | -10.88% |
| 2009 FY | 1.04 Million USD | -36.78% |
| 2009 Q3 | 1.08 Million USD | -24.62% |
| 2009 Q2 | 1.43 Million USD | -2.64% |
| 2008 Q1 | 1.45 Million USD | 4.35% |
| 2008 Q4 | 1.65 Million USD | 0.22% |
| 2008 Q2 | 1.66 Million USD | 14.73% |
| 2008 FY | 1.65 Million USD | 18.56% |
| 2008 Q3 | 1.64 Million USD | -1.19% |
| 2007 Q2 | 1.53 Million USD | -0.18% |
| 2007 Q4 | 1.39 Million USD | -3.63% |
| 2007 FY | 1.39 Million USD | -18.11% |
| 2007 Q1 | 1.53 Million USD | -9.85% |
| 2007 Q3 | 1.44 Million USD | -5.57% |
| 2006 Q3 | 1.41 Million USD | -8.31% |
| 2006 FY | 1.7 Million USD | 14.15% |
| 2006 Q1 | 1.37 Million USD | -8.13% |
| 2006 Q2 | 1.54 Million USD | 12.98% |
| 2006 Q4 | 1.7 Million USD | 19.95% |
| 2005 FY | 1.49 Million USD | -9.75% |
| 2005 Q3 | 1.54 Million USD | -13.02% |
| 2005 Q2 | 1.77 Million USD | -9.85% |
| 2005 Q1 | 1.97 Million USD | 19.36% |
| 2005 Q4 | 1.49 Million USD | -3.58% |
| 2004 Q3 | 1.36 Million USD | 2.88% |
| 2004 Q4 | 1.65 Million USD | 21.12% |
| 2004 Q1 | 2.07 Million USD | 62.03% |
| 2004 FY | 1.65 Million USD | 28.84% |
| 2004 Q2 | 1.32 Million USD | -36.19% |
| 2003 Q2 | 1.49 Million USD | 14.83% |
| 2003 Q1 | 1.29 Million USD | -13.11% |
| 2003 FY | 1.28 Million USD | -14.11% |
| 2003 Q4 | 1.28 Million USD | -0.42% |
| 2003 Q3 | 1.28 Million USD | -13.55% |
| 2002 Q4 | 1.49 Million USD | -40.36% |
| 2002 Q2 | 3.28 Million USD | -71.82% |
| 2002 Q3 | 2.5 Million USD | -23.66% |
| 2002 FY | 1.49 Million USD | -86.12% |
| 2002 Q1 | 11.64 Million USD | 8.22% |
| 2001 Q4 | 10.75 Million USD | 6.48% |
| 2001 Q2 | 8.5 Million USD | -10.34% |
| 2001 Q3 | 10.1 Million USD | 18.86% |
| 2001 Q1 | 9.48 Million USD | 230.83% |
| 2001 FY | 10.75 Million USD | 275.39% |
| 2000 FY | 2.86 Million USD | 34.88% |
| 2000 Q4 | 2.86 Million USD | 19.65% |
| 2000 Q3 | 2.39 Million USD | 11.9% |
| 2000 Q2 | 2.14 Million USD | -3.29% |
| 2000 Q1 | 2.21 Million USD | 0.0% |
| 1999 FY | 2.12 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2957.383% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 91.139% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.843% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3.702% |
| Rebus Holdings, Inc. | 5.24 Million USD | 84.0% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.579% |
| Qrons Inc. | 1.48 Million USD | 43.661% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 31.6% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.88% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1776.526% |
| Skye Bioscience, Inc. | 14.07 Million USD | 94.04% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.427% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 91.247% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -98.955% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.324% |
| Intellipharmaceutics International Inc. | 12 Million USD | 93.016% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 78.223% |
| Mesoblast Limited | 188.44 Million USD | 99.555% |
| Marizyme, Inc. | 26.67 Million USD | 96.856% |
| Genus plc | 485 Million USD | 99.827% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 85.645% |
| Pharming Group N.V. | 244.07 Million USD | 99.656% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 58.275% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 66.668% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 77.928% |
| ContraFect Corporation | 32.53 Million USD | 97.422% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 57.668% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 78.088% |
| IMV Inc. | 37.93 Million USD | 97.789% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 92.879% |
| MultiCell Technologies, Inc. | 1617.67 USD | -51748.152% |
| ONE Bio Corp. | 27.49 Million USD | 96.95% |
| Accustem Sciences Inc. | 1.07 Million USD | 22.285% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.917% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 60.345% |
| Q BioMed Inc. | 8.13 Million USD | 89.687% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.989% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 83.701% |
| Biomind Labs Inc. | 1.49 Million USD | 44.033% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.294% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 90.724% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 95.443% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 41.505% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -490.261% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -317.039% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 85.403% |
| GB Sciences, Inc. | 5.41 Million USD | 84.518% |
| Alpha Cognition Inc. | 7.16 Million USD | 88.294% |
| HST Global, Inc. | 593.59 Thousand USD | -41.297% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 33.391% |
| Halberd Corporation | 728.71 Thousand USD | -15.097% |
| Enzolytics Inc. | 365.26 Million USD | 99.77% |
| Agentix Corp. | 2.51 Million USD | 66.592% |
| Resverlogix Corp. | 67.39 Million USD | 98.756% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.812% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 51.066% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 96.611% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 92.954% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 77.116% |
| AVAX Technologies, Inc. | 3.99 Million USD | 78.999% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2942.301% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.937% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -251.443% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 77.54% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -23.192% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 69.069% |
| Kadimastem Ltd | 3.5 Million USD | 76.07% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1153.167% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.331% |
| BioStem Technologies, Inc. | 15.9 Million USD | 94.727% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -80.489% |
| LadRx Corporation | 2.2 Million USD | 61.885% |
| Cell Source, Inc. | 15.8 Million USD | 94.694% |
| Regen BioPharma, Inc. | 5.45 Million USD | 84.632% |
| Regen BioPharma, Inc. | 5.45 Million USD | 84.632% |
| NovAccess Global Inc. | 7.86 Million USD | 89.33% |
| Affymax, Inc. | 8.87 Million USD | 90.545% |
| Itoco Inc. | 1.65 Million USD | 49.265% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 59.117% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 86.134% |
| Mobile Lads Corp. | 1.31 Million USD | 36.145% |
| CytoDyn Inc. | 127.89 Million USD | 99.344% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1906.584% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 46.454% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 92.406% |
| SYBLEU INC | 681.41 Thousand USD | -23.087% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 86.255% |
| International Stem Cell Corporation | 5.27 Million USD | 84.106% |
| Bioxytran, Inc. | 3.24 Million USD | 74.189% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -34.024% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 81.834% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.954% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.233% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 58.589% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 84.689% |
| Neutra Corp. | 973.52 Thousand USD | 13.846% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.109% |
| PureTech Health plc | 125.58 Million USD | 99.332% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 77.676% |
| IXICO plc | 1.9 Million USD | 55.863% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 95.914% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.188% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Cellectis S.A. | 249.36 Million USD | 99.664% |